Enzymatic vitreous disruption refers to cleaving the vitreoretinal junction by enzymatic means, thereby inducing posterior vitreous detachment (PVD) and liquefaction of the vitreous gel. Several enzymes have been proposed in this respect, including chondroitinase, hyaluronidase, dispase, and plasmin. In an experimental setting, chondroitinase induced PVD and was helpful in removing epiretinal membranes but no further data have been reported yet.
Introduction
Enzymatic vitreous disruption is among the top five wish list of medical and surgical retina specialists. Separating the vitreous cortex completely from the retina by pharmacological means would be a major achievement compared to today's mechanical techniques of vitrectomy.
As incomplete vitreoretinal separation and vitreoschisis play a central role in the progression of commonly and potentially blinding diseases such as diabetic retinopathy and maculopathy, proliferative vitreoretinopathy (PVR) and vitreomacular traction syndromes, induction of complete posterior vitreous detachment (PVD) by pharmacological means has a major impact on both surgical techniques and public health aspects. [1] [2] [3] [4] [5] Enzyme-assisted induction of PVD enables the surgeon to create a clean retinal surface that can currently not be achieved by mechanical means. 6, 7 Moreover, complete vitreoretinal separation without directly approaching the retina and macula by bent needles or forceps would make surgery easier and safer. In children and young adults and in patients with firm vitreoretinal adhesion, complete separation of the vitreous from the retina would be possible. This would help to improve both the anatomical and functional outcome by eliminating remnants of vitreous that act as a scaffold and promotor of persistent and recurrent cellular proliferation. 3, 4 In progressively blinding diseases such as diabetic retinopathy, separating the vitreous from the retina before neovascular and fibrocellular proliferation grow into the vitreous cortex would prevent advanced stages of the disease. 6, 8 Finally, pharmacological vitrectomy holds the potential of improving retinal oxygen levels in hypoxic retinal diseases in a more applicable way compared with mechanical vitrectomy. 9 This is of particular importance given the increasing incidence of diabetic retinopathy in the world. 10 The goal of enzymatic vitreous disruption is to manipulate the vitreous collagen pharmacologically, both centrally achieving liquefaction, as well as along the vitreoretinal interface to induce PVD, and to create a cleavage plane more safely and cleaner than can be achieved by mechanical means. 6 
Enzyme candidates for vitreous disruption
Chondroitinase A 240 kDa chondroitin sulphate proteoglycan is associated with the vitreoretinal interface. 12 The greatest immunoreactivity of this proteoglycan has been observed in regions of firm vitreoretinal adhesion, such as the vitreous base and the papillary margin, suggesting a major role in vitreoretinal adhesion. The enzyme chondroitinase cleaves this proteoglycan and has been studied as an adjunct in vitrectomy in two human donor eyes and in 57 cynomolgus monkeys. 12 Intravitreal injection of the enzyme separated the vitreous from the retina without damaging the inner limiting membrane (ILM). Three monkeys have been followed for 14-16 months after surgery without any adverse effects. 12 Chondroitinase has also been utilized to detach epiretinal membranes in four monkeys, providing evidence that chondroitin sulphate proteoglycan participates in the adhesion of epiretinal membranes to the ILM. 12 Unfortunately, no further pre-clinical or clinical results have been reported yet.
Hyaluronidase
Hyaluronan represents one of the two major macromolecules of the vitreous, 11, 13, 14 and is supposed to maintain the three-dimensional structure of the vitreous gel by coating the collagen fibrils and by bridging them with interconnecting filaments. 15 Hyaluronidase (Vitrase) cleaves hyaluronan and has been suggested to liquefy the vitreous.
A phase III clinical trial has shown that 55 IU of highly purified ovine hyaluronidase (Vitrase) helps to clear eyes with vitreous haemorrhage 1 month after intravitreal application. 16 In a companion article on the safety results, no serious safety issues were reported. 17 In particular, the incidence of retinal detachment was not statistically different between treated eyes and control groups. No assessment, however, was performed in terms of PVD induction, and previous experimental trials of hyaluronidase in rabbits failed to achieve PVD. 18 Dispase Dispase, a neutral 41 kDa protease isolated from Bacillus polymyxa, selectively cleaves type IV collagen and fibronectin. 19 The enzyme facilitated PVD in enucleated porcine and human eyes, and in pig eyes in vivo. 20, 21 However, partial digestion of the ILM was observed in post-mortem eyes, exposing the mosaic pattern of Mü ller cell endfeet. 20 In rabbit eyes in vivo and in human eyes 15 min before enucleation, intravitreal injection of dispase caused intraretinal haemorrhages and ILM disruption at bleeding sites. 22 In this series, there was no effect of dispase on PVD induction.
As dispase acts on type IV collagen, forming the main structural protein of basement membranes including the ILM, changes of the inner retina following application of the enzyme are not surprising. 20 The enzyme has been shown to effectively induce PVR in rabbits in a dosedependent fashion, known as the dispase model of PVR, and future studies need to investigate the safety of dispase before clinical studies can be considered.
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Plasmin
Plasmin is a non-specific serine protease mediating the fibrinolytic process. It acts also on a variety of glycoproteins including laminin and fibronectin, both of which are present at the vitreoretinal interface. [24] [25] [26] In 1993, PVD could be achieved in rabbit eyes by intravitreal injection of the enzyme followed by vitrectomy. 27 In 1999, Hikichi and co-workers confirmed complete PVD after injection of 1 U plasmin and 0.5 ml SF 6 gas in the rabbit model, without evidence of retinal toxicity. 28 We investigated the effect of plasmin in porcine post-mortem eyes and in human donor eyes. In porcine eyes, we observed a dose-dependent separation of the vitreous cortex from the ILM after intravitreal injection, without additional vitrectomy or gas injection. 29 In scanning electron microscopy, a bare ILM was achieved by 1 U of porcine plasmin 60 min after injection, and with 2 U of plasmin 30 and 60 min after injection, respectively. In control fellow eyes which were injected with BSS, the cortical vitreous remained attached to the retina. 29 In human donor eyes, 2 U of human plasmin from pooled plasma achieved complete PVD 30 min after injection, whereas the vitreoretinal surface of the fellow eyes was covered by collagen fibrils. 30 In both studies, transmission electron microscopy revealed a clean and perfectly preserved ILM in plasmin-treated eyes, and no evidence of inner retinal damage. 29, 30 Li and colleagues confirmed these results, and reported a reduced immunoreactivity of the vitreoretinal interface for laminin and fibronectin following application of plasmin. 31 In an experimental setting simulating the application of plasmin as an adjunct to vitrectomy, we injected human donor eyes with 1 U of plasmin, followed by vitrectomy 30 min thereafter. 7 All plasmin-treated eyes showed complete PVD, whereas the control eyes which were vitrectomized conventionally had various amounts of the cortical vitreous still present at the vitreoretinal interface ( Figure 1 ). 7 Plasmin is not available for clinical application, and alternative strategies have been pursued to administer the enzyme in vitreoretinal surgery. Tissue plasminogen activator was injected into the vitreous in an attempt to generate plasmin by intravitreal activation of endogenous plasminogen. In an animal model in rabbit eyes, complete PVD was observed in all eyes treated with 25 mg tissue plasminogen activator. 32 Breakdown of the blood-retinal barrier was necessary to allow plasminogen to enter the vitreous, and this was induced by cryocoagulation. 32 In two clinical pilot studies, 25 mg tissue plasminogen activator was injected into the vitreous of patients with proliferative diabetic retinopathy 15 min before vitrectomy. 33, 34 The results of both studies, however, were contradictory in terms of PVD induction and clinical benefit. Recently, Peyman's group demonstrated PVD induction in rabbit eyes by an intravitreal administration of recombinant lysine plasminogen and recombinant urokinase. 35 Autologous plasminogen purified from the patient's own plasma by affinity chromatography was converted to plasmin by streptokinase in vitro. Autologous plasmin enzyme (APE; 0.4 U) was injected into the vitreous in patients with paediatric macular holes, diabetic retinopathy, and stage 3 idiopathic macular holes, followed by vitrectomy after 15 min. [36] [37] [38] All APE-treated eyes achieved spontaneous or easy removal of the posterior hyaloid including one eye that had vitreoschisis over areas of detached retina.
Recombinant microplasmin (ThromboGenics Ltd, Dublin), a truncated molecule containing the catalytic domain of human plasmin has been administered successfully into the vitreous of human 39 and porcine post-mortem eyes, and in rabbit and cat eyes in vivo. 39, 40 In all experimental settings, complete PVD was achieved in a dose-dependent fashion. No alteration of the inner retina was seen, and there was no change in antigenity of neurons and glial cells.
Microplasmin was further tested in different animal models sponsored by the manufacturer, and a first clinical trial was designed.
The MIVI trial investigated the effect of microplasmin given 1 h, 1 day, and 1 week before vitrectomy in patients with vitreomacular traction. Although the results of this trial have not been published yet, it can be said that the pharmacological effect of microplasmin was promising and further trials are now underway to show the efficacy and safety of this recombinant enzyme in different clinical settings. .
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Summary
There are at least three reasons to pursue enzymatic vitreous disruption. First, some retinal diseases that are currently treated by mechanical manipulation of the vitreoretinal interface could be managed more safely by pharmacological technique. Second, enzymatic vitreous disruption may achieve better anatomical and thus potentially functional results by creating a cleaner cleavage plane between the vitreous and the retina than can currently be achieved by vitrectomy techniques. 6, 7 This is of particular importance in eyes with incomplete removal of the cortical vitreous from the retina, and in eyes with vitreoschisis, such as diabetic eyes. 1, 8 Third, as incomplete PVD has been shown to be associated with development of aggressive fibrovascular proliferation and macular oedema, pharmacological induction of complete PVD could prevent progression of diabetic retinopathy if given before advanced stages of diabetic eye disease, both by eliminating the scaffold for cellular proliferation and by improving retinal oxygen levels.
Plasmin holds the promise of inducing complete PVD without morphological alteration of the retina. Several independent studies confirmed a dose-dependent and complete vitreoretinal separation, associated with perfect preservation of the ultrastructure of the ILM and the retina. 7, [27] [28] [29] [30] 39 In addition, a dose-dependent liquefaction of the vitreous induced by microplasmin has been demonstrated by dynamic light scattering in dissected porcine vitreous and in intact pig eyes. 41 The combination of PVD induction and liquefaction in one molecule is one major advantage of plasmin and microplasmin compared with other enzymes tested, as liquefaction alone carries the risk of tractional retinal breaks. So far, the safety profile and the effects of microplasmin and plasmin are promising. However, clinical trials will demonstrate whether practice can hold what theory has promised.
